Identification of transcriptomic determinants to predict the efficacy of anti-EGFR treatment of colorectal cancer patients.

Abstract

130Background: It is now well known that in colorectal cancer (CRC) activating mutations in KRAS, NRAS, and BRAF confer resistance to anti-EGFR therapy. However, only ~ 40% of patients with RASWT (...